Haixin Huang

机构：Liuzhou Maternal and Child Health Hospital, Liuzhou General Hospital, Fourth Affiliated Hospital of Guangxi Medical University

发表论文 12 篇 · 总被引 420 次 · h-index 5

代表论文

• Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) (2021 · Journal of Clinical Oncology · 被引 360)
• Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study. (2018 · Journal of Clinical Oncology · 被引 15)
• [Clinical observation on treatment of 75 mid-late stage cancer patients with yanshu Injection]. (2006 · PubMed · 被引 14)
• New biomarkers and therapeutic targets of human liver cancer: Transcriptomic findings (2021 · BioFactors · 被引 13)
• Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study. (2019 · Journal of Clinical Oncology · 被引 8)
• Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma. (2020 · Journal of Clinical Oncology · 被引 4)